{"entity":{"id":"cellular-kinetics-and-persistence","kind":"term","name":"Cellular kinetics and persistence","aka":["living-drug kinetics","cell-therapy abundance and function","cell dose and persistence"],"tldr":"A living cell therapy can change its number, location and state after administration. The starting dose, a sampled cell count and useful function are different measurements.","summary":"After a cell infusion, measured abundance depends on division, survival and redistribution. In vivo engineering may also continue to generate newly engineered cells. A blood sample describes one compartment and time; it cannot count all cells in the body or establish entry into a tumor. Detectable receptor-encoding sequences, viable receptor-positive cells, persistent markers and functional activity should be reported separately.","asOf":"2026-11-12","links":[{"label":"FDA: CAR T-cell product design, testing and clinical pharmacology guidance (2024)","url":"https://www.fda.gov/media/156896/download"},{"label":"NCI: T-cell transfer therapy and harms","url":"https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/t-cell-transfer-therapy"},{"label":"Liu et al.: one cord-blood CAR-NK construct in lymphoid tumors (2020)","url":"https://doi.org/10.1056/NEJMoa1910607"},{"label":"Phase I Study of ROR1-Specific CAR-T Cells in Advanced Hematopoietic and Epithelial Malignancies. (2025)","url":"https://pubmed.ncbi.nlm.nih.gov/39466024/"},{"label":"NCI: Tumor Biology and Microenvironment Research","url":"https://www.cancer.gov/about-nci/organization/dcb/research-portfolio/tbmr"},{"label":"FDA long-term follow-up after human gene therapy (January 2020)","url":"https://www.fda.gov/media/113768/download"}],"tags":[],"related":["car-t","car-nk-macrophage","nk-cell-therapy","in-vivo-car-t","t-cell-exhaustion-term"],"cancers":[],"sections":["cell-therapy"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["FDA CAR T-cell guidance treats exposure/kinetics, pharmacodynamic response, immunogenicity, identity, viability and potency as distinct assessments. Blood concentration-time measurements and optional disease-tissue sampling answer different distribution questions. A sequence assay is not automatically a count of viable cells expressing a functional surface receptor.","Keep the measurement method, time, compartment, units and denominator attached. A receptor-positive percentage can fall while absolute receptor-positive cells per microliter remain unchanged if the sampled denominator increases. Neither measure alone establishes an unchanged total-body cell population, tumor entry or antitumor benefit.","An administered cell dose is an input. The dose of a vector or particle used for in vivo engineering does not directly specify the later number of engineered cells. Autologous means the recipient’s own cells; allogeneic means cells from another person. Engineering outside versus inside the body is a separate axis; a prepared delivery product can engineer the recipient's own cells.","Expansion and persistence can prolong useful activity or harmful recognition. Stopping further administration does not instantly remove living cells or reverse an injury already triggered. A safety switch addresses a specified control mechanism; cell elimination, receptor shutoff and treatment of downstream inflammation are different interventions.","In the Liu cord-blood CAR-NK study, low-level detection at least 12 months after treatment belonged to a construct with IL-15 and an inducible caspase-9 switch. It does not establish the behavior of every NK-cell source or equate marker detection with continuing useful function.","In a fictional pair of matched blood samples, 20 per cent of 100 viable T cells per microlitre and 10 per cent of 200 both give 20 receptor-positive viable T cells per microlitre. The percentage fell because its denominator doubled; the concentration did not. This conclusion requires comparable collection, volume and viable-cell gates. It says nothing about the total number of cells in the body, tumour entry or continued target-cell killing. Genetic copies, surface receptor, viable cells and useful function remain separate measurements.","Cells respond biologically to signals, without intention; more cells do not by themselves establish better or safer treatment. Consider two fictional ready-made products: a carrier that gives receptor instructions to the recipient’s own T cells, and a prepared batch of donor-derived engineered cells. The first can generate autologous cells in vivo; the second supplies allogeneic cells engineered ex vivo. State four things separately: the starting cell family, whose cells they are, where engineering happens and whether cells or an instruction carrier are administered. Neither card establishes available supply, the final engineered-cell population or treatment benefit. NK and NKT name different cell families; an added receptor does not erase the recipient cell’s other inputs.","A rise in engineered cells in blood with few found in two tumour biopsies leaves distribution and infiltration unresolved. Blood abundance is not entry into a mass of tissue, and a biopsy represents its sampled place and time. If a receptor works in a simple culture but killing falls in a more complex model with the target still present, investigate access, cell state and the model’s other features with controlled perturbations. The contrast alone does not identify a macrophage, vessel or signalling pathway as the cause, or show that more expansion will solve it. Expression of PD-1, LAG-3, TIM-3 or TIGIT, or a count of macrophages or suppressor cells, does not by itself establish which input caused the functional difference. Trafficking toward a site and infiltration into tissue are different steps, and vessel number does not measure perfusion. Chronic stimulation, low oxygen, limited nutrients and inhibitory signals are different hypotheses; exhaustion describes cell states rather than physical tiredness.","Compare time courses rather than labels when interpreting reversibility. Antibodies also take time to clear after dosing stops. In an engineered-cell product, carrier exposure, instructions, receptor protein, living cells and inflammation can have different durations. Stopping the next administration, reducing one signal, removing the cells and reversing an established injury are separate claims."],"category":"Treatment jargon"},"route":"/terms/cellular-kinetics-and-persistence/","neighbours":{"technology":[{"id":"armored-car","kind":"technology","name":"Armoured, logic-gated & next-gen CARs","route":"/technologies/armored-car/"},{"id":"car-nk-macrophage","kind":"technology","name":"CAR-NK & CAR-macrophage","route":"/technologies/car-nk-macrophage/"},{"id":"car-t","kind":"technology","name":"CAR-T cell therapy","route":"/technologies/car-t/"},{"id":"safety-switch-car-t","kind":"technology","name":"Cell-therapy safety switches","route":"/technologies/safety-switch-car-t/"},{"id":"in-vivo-car-t","kind":"technology","name":"In vivo CAR-T","route":"/technologies/in-vivo-car-t/"},{"id":"logic-gated-therapeutics","kind":"technology","name":"Logic-gated therapeutics (AND, NOT gates)","route":"/technologies/logic-gated-therapeutics/"},{"id":"nk-cell-therapy","kind":"technology","name":"NK cell therapy and CAR-NK","route":"/technologies/nk-cell-therapy/"},{"id":"t-cell-engager","kind":"technology","name":"T-cell engagers (bispecific)","route":"/technologies/t-cell-engager/"},{"id":"tcr-t","kind":"technology","name":"TCR-T cell therapy","route":"/technologies/tcr-t/"},{"id":"til-therapy","kind":"technology","name":"TIL therapy","route":"/technologies/til-therapy/"}],"term":[{"id":"endogenous-promoter-payload-control","kind":"term","name":"Control of cell payloads by endogenous promoters","route":"/terms/endogenous-promoter-payload-control/"},{"id":"ex-vivo-cell-expansion","kind":"term","name":"Ex vivo cell expansion","route":"/terms/ex-vivo-cell-expansion/"},{"id":"synthetic-cytokine-receptors","kind":"term","name":"Synthetic cytokine receptors","route":"/terms/synthetic-cytokine-receptors/"},{"id":"t-cell-exhaustion-term","kind":"term","name":"T-cell exhaustion and CAR-T persistence","route":"/terms/t-cell-exhaustion-term/"}],"section":[{"id":"cell-therapy","kind":"section","name":"Cell Therapy","route":"/fronts/cell-therapy/"}]}}